Skip to content
sellWeak cluster of 210b5-1 plan

Julie Krop sold $125k of AQST

director at Aquestive Therapeutics, Inc.. 25,000 shares at an average of $5.02, traded Jun 23, 2026, filed Jun 24, 2026.

Warning score
19
Value
$125k
25,000 shares
Holdings after
0
-100% from before
From 52-week low
+71%
low $2.95, close $5.03
From 52-week high
-33%
high $7.49, as of Jun 23, 2026

Score components

  • Role
    Director
    +15
  • Trade size
    $125k at market
    +11
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AQSTOct 9, 2026 · close 4.78
Since filing Jun 24, 2026: -4.2%SPY +6.4% · excess -10.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001214659-26-007677, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 23, 2026MOption exercise
Common Stock10b5-1
+25,000$0.71$18k25,000Jun 24, 2026
Jun 23, 2026SOpen-market sale
Common Stock10b5-1
-25,000$5.02$125k0Jun 24, 2026
Jun 23, 2026MOption exercise
Non-Qualified Stock Option (right to buy)derivative10b5-1
-25,000$0.00$00Jun 24, 2026

Related signals

Other insiders at Aquestive Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$120k
25,000 shares
-4%
0Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Sherry Korczynski
Chief Commercial Officer
$46k
8,750 shares
-4%
15Weak
AQSTsell10b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$107k
25,000 shares
-4%
15Weak
AQSTsell10b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$100k
25,000 shares
-4%
23Weak
AQSTsell 210b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$104k
25,000 shares
-4%
11Weak
AQSTsell10b5-1
Aquestive Therapeutics, Inc.
Daniel Barber
President and CEO
$35k
8,257 shares
-1%
52Moderate
AQSTsell 7
Aquestive Therapeutics, Inc.
Cassie Jung
Chief Operating Officer
$191k
45,791 shares
-14%
38Weak
AQSTsell 7
Aquestive Therapeutics, Inc.
Sherry Korczynski
Chief Commercial Officer
$66k
15,741 shares
-6%
55Moderate
AQSTsell 7
Aquestive Therapeutics, Inc.
A Ernest Toth Jr
Chief Financial Officer
$243k
58,254 shares
-13%
40Moderate
AQSTsell 7
Aquestive Therapeutics, Inc.
Melina Cioffi
SVP, Regulatory Affairs
$106k
25,311 shares
-8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Julie Krop sold $125k of AQST | InsiderTell